Sunless Tanning Peptide Melanotan II

Melanotan products are purchased via the Internet and have three main formulations (Melanotan I, Melanotan II, and bremelanotide). Melanotan I increases melanogenesis and eumelanin content to produce sunless tanning. It also increases skin pigmentation but also produces spontaneous penile erections and sexual stimulation. Bremelanotide is a variation of Melanotan II that is specifically designed for sexual stimulation. This unique case highlights the potential of systemic toxicity with sympathomimetic excess, rhabdomyolysis, and renal dysfunction from Melanotan II use.

Melanotan II was developed originally as potential preventative treatments for various forms of skin cancer. It was thought that by artificially stimulating the internal tanning process among members of the population that were at high risk to develop skin cancer due to sun exposure that one may be able to lower the chances of these individuals from developing the disease later in life. While these findings have been relatively inconclusive in terms of the original intent of the product a few secondary uses for the drug have been found and are now utilized by many.

The main purpose that both Melanotan and Melanotan II are now administered for is their ability to act as a tanning agent. Both are synthetic hormones that once introduced into the body are able to cause a reaction within it that is similar to the natural tanning process that one goes through without the risks or need for sunlight to be present, while remembering that some of the benefits of exposure to the sun will also not be present. Along with the benefits of providing a tan without the need for extensive exposure to sunlight as well as improved sexual performance and/or desire, Melanotan II also may help to decrease the appetite via targeting an appetite-suppression receptor in the brain. This effect is not an overwhelming one but is noticeable for the majority of users and desirable for many. The duration of the tanning effect of the drug once a user ceases administering it will once again depend on several factors. The majority of users however will notice that the tan achieved with the drug will fade and become unnoticeable within four to eight weeks after ceasing the administration of the drug.

Melanotan II libido enhancement and sexual performance

The libido enhancement and sexual performance benefits will fade much quicker along with the appetite suppressing effect. The tan that is created is considered a “natural” one in both the reaction that causes it in the body as well as the outward appearance of the skin once the drug has taken full effect. It should be noted however that to achieve the full effect of the hormones one will still have to expose themselves to sunlight and/or artificial tanning beds, etc. Unlike Melanotan however, Melanotan II has libido and sexual performance enhancing capabilities. This is due to Melanotan II having the metabolite Bremelanotide. Bremelanotide is currently under research as a possible treatment for various forms of sexual dysfunction, including both sexual arousal disorders as well as erectile dysfunction. Since however Bremelanotide has not been made available for use by the general public, for those wanting to reap its benefits in terms of its sexual performance improvements, Melanotan II is the only option at this point. It is believed that the source of this improvement in both sexual performance and arousal is the action of the hormone on the hypothalamus of the user. This, however, is still a theory in need of further investigation.

For most individuals, during the loading phase with the hormone, a range of between 0.015 to 0.02 milligrams per kilogram of body weight per injection should be sufficient. These injections would take place anywhere from twice daily to as infrequently as once every other day or longer. For the maintenance phase many individuals will find that a dose of approximately 0.01 milligrams per kilogram of body weight administered once every few days should be sufficient to maintain the effects of the hormone. As stated however, the reactions to Melanotan II are highly individualized so experimentation when first using this hormone will be necessitated. As always, lower doses should be utilized to begin with and increased as needed and as one is able to gage their tolerance for the drug

Clinical trials to determine efficacy of the drugs have typically used dosages up to 0.21mg/kg daily for Melanotan (16mg for a 75kg (165lb) individual), and up to 0.03mg/kg daily for Melanotan II (2.25mg for a 75kg (165lb) individual). More typically however, trials have used the dosages of 0.16mg/kg (12mg) and 0.025mg/kg (1.875mg) respectively. At this level of dosage, one such study involving Melanotan indicated the following incidences of side effects from subjects:

• Nausea 85%
• Facial Flushing 75%
• Fatigue 44%
• Vomiting 26%
• Injection site reactions 13%
• Zero incidence of erections
• No change in vital signs or haematological parameters, blood biochemistry (liver and renal function)

As is the case with any drug use, the user is ideally looking to minimise unwanted side effects, whilst still achieving an acceptable outcome. With this in mind, I would suggest that a tapering up of dosages is used in order to assess the individual's personal tolerance to the side effects.

Both MT and MT II can be used for extended periods, whereby there is an initial daily administration of perhaps 2-3 weeks or until desired level of pigmentation has been achieved, followed by a maintenance phase of two injections per week.

.

More peptide information